Antiemetics in children receiving chemotherapy. MASCC/ESMO guideline update 2009

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Supportive Care in Cancer

• Publication date

  2011-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s00520-010-0994-7PMID 20824481
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Aprepitant in adolescent patients for prevention of chemotherapy‐induced nausea and vomiting: A randomized, double‐blind, placebo‐controlled study of efficacy and tolerability

  2009cited by this paper
• Safety of ondansetron loading doses in children with cancer

  2008influential reference
• Palonosetron hydrochloride is an effective and safe option to prevent chemotherapy-induced nausea and vomiting in children.

  2008cited by this paper
• Comparative activity of antiemetic drugs.

  2007cited by this paper
• A double-blind, crossover, randomized dose-comparison trial of granisetron for the prevention of acute and delayed nausea and emesis in children receiving moderately emetogenic carboplatin-based chemotherapy

  2007influential reference
• Contribution to the treatment of nausea and emesis induced by chemotherapy in children and adolescents with osteosarcoma

  2006cited by this paper
• Acute and delayed nausea and emesis control in pediatric oncology patients

  2006cited by this paper
• A pilot study of ondansetron plus metopimazine vs. ondansetron monotherapy in children receiving highly emetogenic chemotherapy: a Bayesian randomized serial N-of-1 trials design

  2006cited by this paper
• American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006.

  2006cited by this paper
• The 2004 Perugia Antiemetic Consensus Guideline process: methods, procedures, and participants

  2005cited by this paper
• Aseptic Osteonecrosis in Children and Adolescents Treated for Hemato-Oncologic Diseases: A 13-Year Longitudinal Observational Study

  2005cited by this paper
• Antiemetics in children receiving chemotherapy

  2005influential reference
• Antiemetics in children receiving chemotherapy

  2005cited by this paper
• A PROSPECTIVE RANDOMIZED TRIAL OF THE ANTIEMETIC EFFICACY AND COST-EFFECTIVENESS OF INTRAVENOUS AND ORALLY DISINTEGRATING TABLET OF ONDANSETRON IN CHILDREN WITH CANCER

  2005cited by this paper
• Tropisetron: Optimal dosage for children in prevention of chemotherapy‐induced vomiting

  2005cited by this paper
• Osteonecrosis: A treatment related toxicity in childhood acute lymphoblastic leukemia (ALL)—experiences from trial ALL‐BFM 95

  2005cited by this paper
• Single-dose oral granisetron versus multidose intravenous ondansetron for moderately emetogenic cyclophosphamide-based chemotherapy in pediatric outpatients with acute lymphoblastic leukemia.

  2004cited by this paper
• Single-Dose Oral Granisetron Versus MultiDose Intravenous Ondansetron for Moderately Emetogenic Cyclophosphamide-Based Chemotherapy in Pediatric Outpatients with Acute Lymphoblastic Lukemia

  2004cited by this paper
• Prophylaxis of acute chemotherapy‐induced nausea and vomiting in children with cancer: What is the evidence?

  2004cited by this paper
• In vitro effects of combination chemotherapy on osteoblasts: implications for osteopenia in childhood malignancy.

  2002cited by this paper
• Survey ranking of emetogenic control in children receiving chemotherapy.

  2000cited by this paper
• An increased loading dose of ondansetron: a north european, double-blind randomised study in children, comparing 5 mg/m2 with 10 mg/m2.

  1996cited by this paper
• Comparison of dexamethasone and metoclopramide as antiemetics in children receiving cancer chemotherapy.

  1996cited by this paper
• Randomized Double‐Blind Crossover Ondansetron‐Dexamethasone versus Ondansetron‐Placebo Study for the Treatment of Chemotherapy‐Induced Nausea and Vomiting in Pediatric Patients with Malignancies

  1995cited by this paper
• [Antiemetic efficacy of granisetron in pediatric cancer treatment--(2). Comparison of granisetron and granisetron plus methylprednisolone as antiemetic prophylaxis].

  1993cited by this paper
• Chlorpromazine with and without lorazepam as antiemetic therapy in children receiving uniform chemotherapy.

  1993cited by this paper
• Ondansetron as prophylaxis for chemotherapy and radiotherapy-induced emesis in children.

  1992cited by this paper
• Antiemetic therapy for chemotherapy-induced vomiting: metoclopramide, benztropine, dexamethasone, and lorazepam regimen compared with chlorpromazine alone.

  1989cited by this paper
• Chemotherapy‐related nausea and vomiting: Etiology and management

  1989cited by this paper
• Methylprednisolone for chemotherapy-induced emesis: a double-blind randomized trial in children.

  1986cited by this paper
• Antiemetics in children receiving cancer chemotherapy: a double-blind prospective randomized study comparing metoclopramide with chlorpromazine.

  1986cited by this paper

• Development of 3D printed dexamethasone chewable tablets for prophylaxis of chemotherapy-induced nausea and vomiting in children

  2025cites this paper
• Comparison of oral aprepitant and intravenous fosaprepitant for prevention of chemotherapy-induced nausea and vomiting in pediatric oncology patients: a randomized phase III trial

  2024cites this paper
• Safety and Tolerability of a 3-Day Fosaprepitant Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Patients: Results of an Open-Label, Single-Arm Phase 4 Trial

  2024cites this paper
• [Update of guidelines of the AFSOS, SFRO, SFH, SFNCM, SFCE, GFRP for the management of radio-induced nausea and vomiting].

  2024cites this paper
• Palonosetron for prevention of delayed chemotherapy-induced nausea and vomiting in pediatric patients: a meta-analysis

  2023cites this paper
• Antiemetic effects of sclareol, possibly through 5-HT3 and D2 receptor interaction pathways: In-vivo and in-silico studies.

  2023cites this paper
• AFSOS-SFRO-SFH-SFNEP-SFCE-GFRP guidelines on radio-induced nausea and vomiting.

  2022cites this paper
• The emerging role of olanzapine in paediatric CINV control: A review

  2022cites this paper
• Developing the Nausea and Vomiting Thermometer Scale in children with cancer

  2021cites this paper
• Evaluation of clinical outcomes and efficacy of palonosetron and granisetron in combination with dexamethasone in Egyptian patients receiving highly emetogenic chemotherapy

  2021cites this paper
• Phase III study of palonosetron for prevention of chemotherapy-induced nausea and vomiting in pediatric patients.

  2021cites this paper
• COMPARATIVE STUDY BETWEEN THE CLINICAL EFFECT OF PALONOSETRON AND GRANISETRON AS ANTIEMETIC THERAPY IN COMBINATION WITH DEXAMETHASONE IN PATIENTS RECEIVING HIGHLY EMETOGENIC CHEMOTHERAPY REGIMENS

  2021cites this paper
• Principaux effets indésirables des médicaments anticancéreux

  2020cites this paper
• Update Breast Cancer 2019 Part 2 – Implementation of Novel Diagnostics and Therapeutics in Advanced Breast Cancer Patients in Clinical Practice

  2019cites this paper
• Single center experience on efficacy and safety of Aprepitant for preventing chemotherapy-induced nausea and vomiting (CINV) in pediatric Hodgkin Lymphoma

  2019cites this paper
• Palonosetron is a Better Choice Compared With Ondansetron for the Prevention of Chemotherapy-induced Nausea and Vomiting (CINV) in a Resource-limited Pediatric Oncology Center: Results From a Randomized Control Trial

  2019cites this paper
• Pharmacokinetics/pharmacodynamics, safety, and tolerability of fosaprepitant for the prevention of chemotherapy‐induced nausea and vomiting in pediatric cancer patients

  2019cites this paper
• Update Mammakarzinom 2019 Teil 2 – Implementierung neuer Diagnostika und Therapien bei Patientinnen mit fortgeschrittenem Brustkrebs in der klinischen Praxis

  2019cites this paper
• Symptom Management for Nausea-Vomiting in Children Receiving Cancer Treatment: Evidence-Based Practices

  2019cites this paper
• Cannabinoids: the lows and the highs of chemotherapy-induced nausea and vomiting.

  2019cites this paper
• Systematic review of the effectiveness of complementary and alternative medicine on nausea and vomiting in children with cancer: a study protocol

  2019cites this paper
• Breast Cancer 2019 Part 2 – Implementation of Novel Diagnostics and Therapeutics in Advanced Breast Cancer Patients in Clinical Practice Update Mammakarzinom 2019 Teil 2 –

  2019cites this paper
• Update Mammakarzinom 2019 Teil 2 – Implementierung neuer Diagnostika und Therapien bei Patientinnen mit fortgeschrittenem Brustkrebs in der klinischen Praxis

  2019cites this paper
• Easing of Physical Distress in Pediatric Cancer

  2018cites this paper
• Rikkunshito for Preventing Chemotherapy-Induced Nausea and Vomiting in Lung Cancer Patients: Results from 2 Prospective, Randomized Phase 2 Trials

  2018influential citation
• Palonosetron is nonsuperior to ondansetron in acute phase but provides superior antiemetic control in delayed phase for pediatric patients administered highly emetogenic chemotherapy

  2018cites this paper
• Cannabinoids in Patients with Nausea and Vomiting Associated with Malignancy and Its Treatments.

  2018cites this paper
• Management of Chemotherapy-Induced Nausea and Vomiting in Pediatric Patients

  2017cites this paper
• Palonosetron compared with ondansetron in pediatric cancer patients: multicycle analysis of a randomized Phase III study.

  2017cites this paper
• Evaluation of Adequacy of Control of Chemotherapy Induced Vomiting in Paediatric Patients With Cancer at Kenyatta National Hospital

  2017cites this paper
• 2016 updated MASCC/ESMO consensus recommendations: Prevention of acute chemotherapy-induced nausea and vomiting in children

  2016cites this paper
• Palonosetron versus ondansetron for prevention of chemotherapy-induced nausea and vomiting in paediatric patients with cancer receiving moderately or highly emetogenic chemotherapy: a randomised, phase 3, double-blind, double-dummy, non-inferiority study.

  2016cites this paper
• Nausea and Vomiting

  2015cites this paper
• Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy.

  2015cites this paper
• Characterization of Dronabinol Usage in a Pediatric Oncology Population.

  2015cites this paper
• Safety and efficacy of commonly used antiemetics

  2015cites this paper
• An Evidence Practice Gap in Antiemetic Prescription with Chemotherapy

  2014cites this paper
• Comparative effectiveness research in antineoplastic-induced nausea and vomiting control in children.

  2014cites this paper
• Predictors of antiemetic alteration in pediatric acute myeloid leukemia

  2014cites this paper
• Safety and efficacy of aprepitant for chemotherapy‐induced nausea and vomiting in pediatric patients: A prospective, observational study

  2014cites this paper
• SIOP PODC: Recommendations for supportive care of children with cancer in a low‐income setting

  2013cites this paper
• Anti-emetic effects of bioactive natural products

  2013cites this paper
• Comparison of granisetron plus dexamethasone versus an antiemetic cocktail containing midazolam and diphenhydramine for chemotherapy induced nausea and vomiting in children

  2013cites this paper
• After the chemotherapy: potential mechanisms for chemotherapy-induced delayed skeletal muscle dysfunction in survivors of acute lymphoblastic leukaemia in childhood

  2013cites this paper
• State of the Art of Antiemetic Therapy

  2013cites this paper
• Frieda Clinton and colleagues present a study at one children's cancer centre into the use and effectiveness of anti-emetics for patients receiving chemotherapy

  2012cites this paper
• An audit of chemotherapy-induced nausea and vomiting in children.

  2012cites this paper
• Supportive care treatment guidelines: value, limitations, and opportunities.

  2011cites this paper